Long Noncoding RNA Acting as Therapeutic Target for Oxidative Stress-Induced Pancreatic Cancer

Document Type

Book Chapter

Publication Title

Handbook of Oxidative Stress in Cancer: Therapeutic Aspects: Volume 1

Abstract

Pancreatic cancer (PanCa) is a systemic disease with both locally advanced and malignant neoplastic phenotypes and has a poor prognosis. Among all sorts of PanCa, exocrine cancers account for approximately 95%, with Pancreatic Ductal Adenocarcinoma (PDAC) ranking fourth in terms of cancer mortality in the United States. Due to its increasing incidence, it is appraised to become the second leading cause of cancer by 2030. PDAC has a 5-year survival rate of 8%. PanCa, rightly known to be the “King of Cancer, " has mortality/incidence ratio of 98% due to lack of therapeutic advancement. PDAC and its associated hypoxic microenvironment play a major role in the formation of hypoxia-inducible factor-1 (HIF-1), which is highly expressed in 88% of PanCa tissues. Among the several noncoding RNAs, long noncoding RNAs (lncRNAs) are more promising due to their role as effector molecules. lncRNAs were initially considered to be “transcriptional noise” or “garbage” of encoding genes but later found to have crucial roles in transcriptional regulation. lncRNAs play a dual role as tumor suppressive and oncogenic. lncRNAs hold strong promise as novel therapeutic biomarkers due to their oxidative stress (OS)-modulating capacity with regard to ROS generation, as observed in SLC7A11-AS1 and NUTF2P3-001. Knockout of lncRNA by RNAi or siRNA plays a promising role in increasing the OS in cancer cells leading to cell death. In this chapter, we have documented the emerging functions and association of lncRNAs in PanCa-associated OS and their potential implications in cancer diagnosis and therapy.

First Page

1525

Last Page

1557

DOI

10.1007/978-981-16-5422-0_77

Publication Date

1-1-2022

This document is currently not available here.

Share

COinS